Date: 2011-08-25
Type of information: Fundraising
Company: Aleva Neurotherapeutics (Switzerland)
Investors: BioMedInvest AG (Switzerland) - BB BIOTECH VENTURES III, L.P. Initiative Capital Romandie (Switzerland) - private investors
Amount: €9.5 million
Funding type: Series A financing round
Planned used: The proceeds will be used to support the development of Aleva’s pioneering product pipeline for neurostimulation, which is based on the company’s proprietary microDBS™ technology. microDBS™ is a next-generation technology addressing Deep Brain Stimulation therapy, currently a US$ 450 million market with strong double-digit growth rates.
Others:
Therapeutic area: Technology - Services - Neurodegenerative diseases